Novo Nordisk B A/S (NVO) on Monday announced a €432 million investment in its tabletting facility in Monksland, Athlone, Ireland, to expand manufacturing capacity for current and future GLP-1 treatments.
The investment will upgrade and retrofit the existing 45-acre site, enhancing Novo Nordisk's ability to manufacture oral products and positioning Ireland as a key hub for serving markets outside the U.S.
Construction is already underway and is expected to generate up to 500 jobs, with completion phased between late 2027 and 2028.
"With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the US," said Kasper Bødker Mejlvang, EVP CMC & Product Supply, Novo Nordisk.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.